[
  {
    "ts": null,
    "headline": "\"LEQEMBI®\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody \"LEQEMBI®\" (lecanemab) for the treatment of early Alzheimer's disease (AD)*.",
    "url": "https://finnhub.io/api/news?id=5c8373acb0b20c1d5d128d09e99cae858fdc838164c3776d5393120ff9218c36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733355060,
      "headline": "\"LEQEMBI®\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
      "id": 131794521,
      "image": "https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody \"LEQEMBI®\" (lecanemab) for the treatment of early Alzheimer's disease (AD)*.",
      "url": "https://finnhub.io/api/news?id=5c8373acb0b20c1d5d128d09e99cae858fdc838164c3776d5393120ff9218c36"
    }
  },
  {
    "ts": null,
    "headline": "\"LEQEMBI\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
    "summary": "- Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk in Mexico has approved humanized anti-soluble aggregated amyloid-beta monoclonal...",
    "url": "https://finnhub.io/api/news?id=eea1f9ee70a5fe02abd1755ea12369df18c591b5385b73fc758dfb173f3cab17",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733350925,
      "headline": "\"LEQEMBI\" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico",
      "id": 131772944,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "- Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk in Mexico has approved humanized anti-soluble aggregated amyloid-beta monoclonal...",
      "url": "https://finnhub.io/api/news?id=eea1f9ee70a5fe02abd1755ea12369df18c591b5385b73fc758dfb173f3cab17"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock rises Wednesday, still underperforms market",
    "summary": "Biogen Inc. stock rises Wednesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=778ac3ac5f44e49e5c450b1fd2a21d3e5ebf7f2c6894d734eb4c230018253c70",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733332020,
      "headline": "Biogen Inc. stock rises Wednesday, still underperforms market",
      "id": 131788799,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock rises Wednesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=778ac3ac5f44e49e5c450b1fd2a21d3e5ebf7f2c6894d734eb4c230018253c70"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Contrarian Core Fund Q3 2024 Commentary",
    "summary": "Institutional Class shares of Columbia Contrarian Core Fund returned 3.50% (net) during Q3 2024 underperforming the benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=4448573f28abbcd9b387b3b33abd43638e13b96312c195ce517158359eeea9a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733276100,
      "headline": "Columbia Contrarian Core Fund Q3 2024 Commentary",
      "id": 131763279,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2066272044/image_2066272044.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Institutional Class shares of Columbia Contrarian Core Fund returned 3.50% (net) during Q3 2024 underperforming the benchmark. Click here to read the full commentary.  ",
      "url": "https://finnhub.io/api/news?id=4448573f28abbcd9b387b3b33abd43638e13b96312c195ce517158359eeea9a6"
    }
  }
]